CONDYLOX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CONDYLOX (CONDYLOX).
Podofilox, the active ingredient, is an antimitotic agent that binds to microtubule-associated proteins and inhibits microtubule assembly, thereby arresting cell division in metaphase. It also causes necrosis of verrucous tissue by inducing vasoconstriction and ischemia.
| Metabolism | Podofilox undergoes hepatic metabolism via glucuronidation and oxidation, with cytochrome P450 enzymes not significantly involved. Metabolites are excreted renally. |
| Excretion | Renal excretion of unchanged drug and glucuronide conjugates; less than 5% excreted in feces. |
| Half-life | Terminal elimination half-life is 2.5 to 5.3 hours; does not accumulate with topical application. |
| Protein binding | ~70% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd approximately 0.3-0.5 L/kg, indicating distribution into total body water. |
| Bioavailability | Topical application: Systemic bioavailability is minimal (<1%) due to low percutaneous absorption. |
| Onset of Action | Topical: Visible resolution of warts begins within 1-2 weeks, with maximum effect by 4-6 weeks. |
| Duration of Action | Duration of action is related to treatment cycle; repeat applications every 12 hours for 3 consecutive days per week until clearance. |
Apply 0.5% solution or gel twice daily (morning and evening) for 3 consecutive days, then withhold for 4 days; repeat weekly for up to 4 cycles. Max weekly dose: 0.5 mL or 1.5 g of gel. For condylomata acuminata.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for topical use; minimal systemic absorption. |
| Liver impairment | No dose adjustment required for topical use; minimal systemic absorption. |
| Pediatric use | Safety and efficacy not established in children under 18 years; use only if potential benefit outweighs risk. |
| Geriatric use | No specific dose adjustment; use with caution due to potential for skin fragility. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CONDYLOX (CONDYLOX).
| Breastfeeding | It is not known whether podofilox is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Condylox, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. The M/P ratio is unknown. Caution is advised; topical application may minimize infant exposure. |
| Teratogenic Risk | Condylox (podofilox) is classified as FDA Pregnancy Category C. In animal studies, podofilox has been shown to be embryotoxic and teratogenic at high doses. However, there are no adequate and well-controlled studies in pregnant women. Due to the potential for fetal harm, Condylox should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Topical application results in minimal systemic absorption, reducing but not eliminating risk. The drug is not recommended for use in the first trimester. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to podofilox or any component of the formulation.","Use on mucous membranes (e.g., vaginal, anal, oral) or in the urethra.","Pregnancy (category C: risk cannot be ruled out; use only if clearly needed and benefit outweighs risk).","Breastfeeding: not recommended due to potential for systemic absorption and excretion in milk."]
| Precautions | ["For external use only; avoid contact with eyes, mucous membranes, or open wounds.","Do not apply to bleeding, friable, or inflamed lesions.","Systemic absorption may occur with extensive application; avoid use on large areas (>10 cm2) or for prolonged periods.","Discontinue if severe local irritation, pain, or ulceration develops.","Use with caution in immunocompromised patients due to risk of treatment failure or recurrence.","Safety and efficacy in children have not been established."] |
Loading safety data…
| Fetal Monitoring | No specific maternal-fetal monitoring is required for topical Condylox use. However, as with any topical medication, observe for signs of excessive local irritation, bleeding, or secondary infection. If systemic adverse effects occur (rare), monitor for neurological, hematological, or gastrointestinal effects. Fetal monitoring is not routinely indicated due to minimal systemic absorption. |
| Fertility Effects | There are no adequate studies on the effects of podofilox on human fertility. Animal studies have not shown significant adverse effects on fertility at clinically relevant topical doses. However, because podofilox is an antimitotic agent, theoretically it could affect gametogenesis if systemic levels are high, but this is unlikely with topical application. |